MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
Recruiting in Palo Alto (17 mi)
+12 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: MedImmune LLC
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
Research Team
ML
MedImmune LLC
Principal Investigator
MedImmune LLC
Eligibility Criteria
Inclusion Criteria
Age ≥ 18 years
Subjects with histologically confirmed relapsed or refractory DLBCL who have received at least 1 prior rituximab containing chemotherapy regimen but no more than 5 prior lines of therapy
Eastern Cooperative Group (ECOG) performance status of 0 or 1
See 2 more
Treatment Details
Interventions
- AZD9150 (Antisense Oligonucleotide)
- MEDI4736 (PD-L1 Inhibitor)
- tremelimumab (Checkpoint Inhibitor)
Participant Groups
3Treatment groups
Experimental Treatment
Group I: MEDI4736 and tremelimumabExperimental Treatment2 Interventions
Group II: MEDI4736 and AZD9150Experimental Treatment2 Interventions
Group III: MEDI4736Experimental Treatment1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Research SiteAlbuquerque, NM
Research SiteDallas, TX
Research SiteDurham, NC
Research SiteLa Jolla, CA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
MedImmune LLC
Lead Sponsor
Trials
348
Patients Recruited
788,000+
Founded
1988
Headquarters
Gaithersburg, USA
Known For
Biologics research
Top Products
Synagis, FluMist